U.S., Nov. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07918547) titled 'A New ECP Protocol for the Treatment of cGVHD' on Oct. 21.
Brief Summary: At present, cGvHD is the main cause of transplant-related morbidity in patients receiving allogeneic hematopoietic stem cell transplant (allo-HSCT). Extracorporeal photopheresis (ECP) has been recognized as a second-line treatment option for steroid-resistant forms or to reduce the immunosuppressant burden. The more commonly adopted protocol consists of performing ECP procedures on two consecutive days every two weeks initially, and then once a month. The investigators hypothesized that a new ECP protocol consisting of one single apheresis procedure on day 1, p...